Medical Health & Life Science Research News

Idiopathic pulmonary fibrosis - pipeline review, H1 2018 detailed in new research report

Medical Market Research

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function.

Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2018 is latest pipeline review released by HTF MI to provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis, complete with analysis by stage of development, drug target, root cause analysis ,mechanism of action (MoA), route of administration (RoA) and molecule type. 

Get Access to Sample PDF @:…ipeline-review-4 Make an Inquiry about this news

If you are want to study the Idiopathic Pulmonary Fibrosis or intend to be, then this guide will provide you comprehensive outlook. It’s vital for you to keep your knowledge up to date by keeping research and development (R&D) of major players. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide requirement according to your needs. 

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.

Key Players included in the research study are Abeome Corp, AdAlta Ltd, Aeolus Pharmaceuticals Inc, Allinky Biopharma, AnaMar AB, apceth Biopharma GmbH, Asahi Kasei Corp, BerGenBio ASA, Biogen Inc, Bioneer Corp, Boehringer Ingelheim GmbH, BreStem Therapeutics Inc, Bristol-Myers Squibb Co, Celgene Corp, Chiesi Farmaceutici SpA, Compugen Ltd, Cynata Therapeutics Ltd, F. Hoffmann-La Roche Ltd, FibroGen Inc, FibroStatin SL, Galapagos NV, Galecto Biotech AB, GenKyoTex SA, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, Global Blood Therapeutics Inc, iBio Inc, Inventiva, Isarna Therapeutics GmbH, Kadmon Corp LLC, Kasiak Research Pvt Ltd, Kyorin Pharmaceutical Co Ltd, Lung Therapeutics Inc, Medicenna Therapeutics Corp, Merck & Co Inc, Miragen Therapeutics Inc, Mission Therapeutics Ltd, Moerae Matrix Inc, Novartis AG, Nuevolution AB, Nuformix Plc, OliX Pharmaceuticals Inc, Pharmaxis Ltd, Promedior Inc, ProMetic Life Sciences Inc, Pulmatrix Inc, Re-Pharm Ltd, Redx Pharma Plc, Respira Therapeutics Inc, Reviva Pharmaceuticals Inc, Ribomic Inc, Saje Pharma LLC, Samumed LLC, Shionogi & Co Ltd, Sorrento Therapeutics Inc, Taiho Pharmaceutical Co Ltd, Telocyte LLC, Therabron Therapeutics Inc, Unity Biotechnology Inc, Vicore Pharma AB, X-Rx Inc, Yuhan Corp & Zai Lab Ltd. 

Make inquiry @…ipeline-review-4 Make an Inquiry about this news  

The guide features dormant and discontinued projects and covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. 

Idiopathic Pulmonary Fibrosis pipeline guide helps in identifying and tracking emerging and major players moves in the market and their portfolios, enhances decision making capabilities and helps to create effective marketing strategies to gain competitive advantage in health care and pharmaceuticals industry. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The data and information sourced from the databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the latest key developments are captured on a real time basis. 

Access this research report @…mp;report=1131678 Make an Inquiry about this news 

Extracts of Chapters from Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2018 
Chapter 1 , to describe the definition , overview and Therapeutics Development of Idiopathic Pulmonary Fibrosis. 
Chapter2, to analyze the pipeline overview of companies, Universities/Institutes and the product development under by companies, Universities/Institutes. 
Chapter3, Therapeutics Assessment of Idiopathic Pulmonary Fibrosis by Target, Mechanism of Action, Route of Administration and by Molecule Type. 
Chapter4, to display company profile involved in Therapeutics Development. 
Chapter5, Drug profile product description, Mechanism of action and R&D Progress of Idiopathic Pulmonary Fibrosis. 
Chapter 6,7, to describe Idiopathic Pulmonary Fibrosis Appendix, Methodology ,Coverage ,Secondary Research ,Primary Research ,Expert Panel Validation and Contact Us. 

Objective of this study 

- To provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis. 
- To reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 
- The pipeline guide features descriptive drug profiles for the pipeline products which comprises, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. 
- The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis therapeutics and enlists all their major and minor projects. 
- The pipeline guide evaluates Idiopathic Pulmonary Fibrosis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. 
- The guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis 

Reasons to access

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. 
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. 
- Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis. 
- Classify potential new clients or partners in the target demographic. 
- Develop tactical initiatives by understanding the focus areas of leading companies. 
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. 
- Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics. 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. 
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. 

Read Detailed Index of full Research Study at @…peline-review-4 Make an Inquiry about this news 

News From

HTF Market Intelligence ConsultingHTF Market Intelligence...
Category: Market Research Publishers and RetailersCompany about: HTF Market Report is wholly owned brand of HTF market Intelligence Consulting Private Limited which provides next-generation service for organizations with a deep focus on market intelligence, data analytics, and social intelligence, all uniquely delivered under one roof by skilled professionals. By combining and analyzing acquire lucid and most relevant data which would help in better decision-making. We provide your requirements with speed and cost benefit across the world, we are able to achi ...
This email address is being protected from spambots. You need JavaScript enabled to view it.

For more information:

Make an Inquiry about this report HERE!